Cytokinetics Inc. (CYTK)
Q2 2009 Earnings Call
July 28, 2010 04:30 pm ET
Sharon Barbari - EVP, Finance and CFO
Robert Blum - President and CEO
Andy Wolff - SVP, Clinical Research and Development, and CMO
Charles Duncan - JMP Securities
Joel Sendek - Lazard Capital
Mark Monane - Needham & Company
Ritu Baral - Canaccord Genuity
Jeremiah Shepard - Wedbush
George Zavoico - McNicoll, Lewis & Vlak LLC
Good afternoon and welcome ladies and gentlemen to the Cytokinetics, second quarter 2010 conference call. At this time I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the request of the company we will open up the call for questions-and-answers after the presentation, I will now turn the call over to Sharon Barbari, Cytokinetics' Executive Vice President of Finance and CFO. Please go ahead
Good afternoon and thank you for joining the Cytokinetics' senior management team on this conference call today.
Also present during this call are Robert Blum, our President and Chief Executive Officer and Dr. Andrew Wolff, Senior Vice President of Clinical Research and Development and Chief Medical Officer.
Following the forward-looking statement disclaimer, Robert will provide an overview of the past quarter along with an update on the advancement of our development pipeline focused on the biology of muscle function.
Andy will then provide highlights and details on the progress of the company's clinical development program. I will then provide some brief comments with respect to our financials and our investment in research and development activity and Robert will then conclude the call with additional comments regarding our recent activities and discuss the projected company milestones for the remainder of 2010. We'll then open the call for a brief question-and-answer session.